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Abstract
Background: Early screening of type 2 diabetes mellitus (DM) is essential for improved prognosis and effective delay of
clinical complications. However, testing for high glycemia often requires invasive and painful blood testing, limiting its
large-scale applicability. We have combined new, unpublished data with published data comparing salivary glucose levels in
type 2 DM patients and controls and/or looked at the correlation between salivary glucose and glycemia/HbA1c to
systematically review the effectiveness of salivary glucose to estimate glycemia and HbA1c. We further discuss salivary
glucose as a biomarker for large-scale screening of diabetes or developing type 2 DM.
Methods and Findings: We conducted a meta-analysis of peer-reviewed published articles that reported data regarding
mean salivary glucose levels and/or correlation between salivary glucose levels and glycemia or HbA1c for type 2 DM and
non-diabetic individuals and combined them with our own unpublished results. Our global meta-analysis of standardized
mean differences on salivary glucose levels shows an overall large positive effect of type 2 DM over salivary glucose
(Hedge’s g = 1.37). The global correlation coefficient (r) between salivary glucose and glycemia was large (r = 0.49), with
subgroups ranging from medium (r = 0.30 in non-diabetics) to very large (r = 0.67 in diabetics). Meta-analysis of the global
correlation between salivary glucose and HbA1c showed an overall association of medium strength (r = 0.37).
Conclusions: Our systematic review reports an overall meaningful salivary glucose concentration increase in type 2 DM and
a significant overall relationship between salivary glucose concentration and associated glycemia/HbA1c values, with the
strength of the correlation increasing for higher glycemia/HbA1c values. These results support the potential of salivary
glucose levels as a biomarker for type 2 DM, providing a less painful/invasive method for screening type 2 DM, as well as for
monitoring blood glucose levels in large cohorts of DM patients.
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Introduction
Early screening of type 2 diabetes mellitus (DM) is essential for
improved prognosis and effective delay of clinical complications
associated with diabetes, and has been suggested as an important
strategy to lower the incidence of this disease worldwide [1–3]. To
date, urine and blood tests are available for screening type 2 DM.
However, urine tests suffer from several drawbacks. First, increases
in blood sugar levels need to be large to be detected in urine.
Second, urine accumulates over time, and is therefore more
difficult to collect under ‘‘fasting’’ conditions than blood. For these
reasons, blood testing, by needle finger pricks or blood draw,
remains the standard for screening, monitoring and diagnosing
diabetes, despite being invasive and painful. Moreover, these
inconvenient techniques perturb daily life, cause anxiety and are
difficult to do in long-term diabetics due to development of finger
calluses, poor peripheral circulation and risk of infection. Recent
studies have focused on the development of saliva-based tests for
screening or monitoring systemic diseases, including diabetes mellitus
[4–6]. Saliva testing could potentially bypass the issues associated
with both urine and blood tests: it is non-invasive and painless, and
can be performed with ease at any time. Such an approach would
be particularly useful in the young, in the elderly, and for large-
scale screening or epidemiological interventions [7,8]. However,
the effectiveness of saliva-based tests is still under debate.
Several primary studies have explored the use of salivary glucose
to measure glycemia, with varying success [9]. In general, salivary
glucose levels in type 2 DM patients seem to be higher than in
non-diabetic controls [10–22]; however, this finding remains
controversial, as in other studies no significant differences were
detected [23–25], or only detected in DM patients that had poor
metabolic control [26,27].
The correlation between salivary glucose and blood variables
like glycemia or glycated hemoglobin (HbA1c) across type 2 DM
and non-diabetic studies also shows some inconsistency in the
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available bibliography. Among type 2 DM patients, some studies
point to a high to medium strength correlation of salivary glucose
with glycemia [9,13,20,21] despite other studies not finding any
meaningful association [12,24,25,28] or, at most, a very weak one
[18] and sometimes only significant in type 2 DM patients with a
bad metabolic control of the disease [11,19]. Only a few studies
have examined the correlation between salivary glucose and
HbA1c, in type 2 DM patients, and found a medium strength
correlation [13,21]. Finally, in non-diabetic individuals, some
studies report that salivary glucose levels do not seem to be clearly
correlated with glycemia or HbA1c [18,28,29] although others
claim the opposite [20] or, at least, show a medium strength
correlation between salivary glucose and glycemia [13,21,30].
These results have led some authors to suggest that monitoring the
salivary glucose level can be useful to evaluate the glycemic status
of type 2 diabetic patients [9,13,20,21,30] and potentially to screen
for early diabetes [13,20], while others support that type 2 DM has
an effect on salivary glucose but reject the idea of a consistent and
direct relationship between unstimulated salivary glucose and
glycemia [12,19,25,28,29].
With the latter in mind, we have performed a meta-analysis by
combining published data on comparisons of mean salivary
glucose levels in type 2 DM and healthy individuals, correlation
studies between saliva glucose levels and glycemia/HbA1c, as well
as our own unpublished results, to systematically assess whether
salivary glucose can be used effectively to estimate blood glucose
levels. We further discuss the potential of this approach for the
diagnosis of early and late type 2 DM, and its possible use as a
biomarker for diabetes or developing diabetes type 2 in large
cohorts.
Materials and Methods
The unpublished results included in this systematic review and
meta-analysis came from an original cross-sectional observational
study performed at our dental clinic campus. Population, saliva
collection and processing, salivary glucose measurement, blood
collection and measurements, and statistical analysis sections
below refer to our original study.
Population
Ethical permission for conducting this study was obtained from
Egas Moniz Ethic Committee of Egas Moniz Cooperativa de
Ensino Superior. Each participant signed the approved written
informed consent where the purpose of the research was clearly
stated; participation was entirely voluntary. Participants were
divided in two different groups (Table 1): The first group consisted
of 45 adult individuals of both sexes with a previous diagnosis of
type 2 DM who were randomly selected from the Egas Moniz
campus dental clinic patient’s population, Monte de Caparica,
Portugal. The second group included 16 adult individuals of both
sexes without the disease (control) randomly selected from the
Monte de Caparica population, Portugal. Subjects with any other
pathology/disease that could affect salivary glands function or with
gingivitis at the time of the study were not included. Other exclusion
criteria were pregnancy and alcoholism. Participants were asked to
fast and abstain from smoking in the night and in the morning
prior to the sampling.
Saliva collection and processing
Total unstimulated saliva was collected in the early morning
from fasting subjects using the spitting method. Once the collected
saliva filled at least 2 ml of a sterile standard container, it was
centrifuged at 10.000 rpm for 30 minutes at 4uC. The sediment
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was discarded and the samples were kept on ice and measured for
glucose.
Salivary glucose measurement
Salivary glucose determination was performed with the
colorimetric kit Glucose (GO) Assay (Sigma-Aldrich, Inc.) based
on glucose-oxidase reaction. The standard protocol was adapted
for 300 ml microplates wells and five glucose solutions with the
following concentrations: 0, 5, 10, 15 and 20 mg/ml being used as
standards. Absorbance values were measured at 540 nm (Bio-Rad
microplate reader M680) as suggested in the manufacturer’s
protocol.
Blood collection and measurements
A venous blood sample was obtained from each subject
immediately after saliva collection and kept in a tube containing
EDTA. Glycemia and HbA1c were measured through the
following methods: Glycemia: electrochemical coulometry using
a glucosimeter (Freestyle Precision - Abbots Diabetes Care Inc),
yielding blood glucose in milligrams per deciliter (mg/dL), HbA1c:
High Pressure Liquid Chromatography (D-10 Hemoglobin testing
system – Bio-Rad Inc.), which gives the % of HbA1c fraction.
Statistical analysis
The normal distribution of the variables was confirmed by
Kolmogorov-Smirnov test before the use of a Student t test for
independent samples. Summary statistics obtained from the data
included the mean and standard deviation (SD), and differences
between samples were considered significant when p#0.05.
Calculations were done using the statistical software SPSS version
19.0 (IBM, USA).
Literature search strategy
We performed a systematic search of PubMed (title search),
Google Scholar (title search) and http://b-on.pt (title and keyword
search) for peer-reviewed articles about comparisons of salivary
glucose values on healthy/type 2 DM subjects and for peer-
reviewed articles containing data on the correlation of salivary
glucose with glycemia or HbA1c, published and available online as
full text before July 2013. A complementary search was performed
within the references cited by selected articles.
Mean salivary glucose levels. The search terms used to
screen for articles about the effect of diabetes mellitus type 2 on
salivary glucose were ‘‘salivary and glucose’’, ‘‘glucose and saliva’’,
‘‘salivary and diabetic’’, ‘‘salivary and diabetes’’, ‘‘diabetes and
salivary and glucose’’ and ‘‘diabetes and saliva and glucose’’.
Correlations with salivary glucose levels. The search
terms applied to retrieve articles relevant to salivary glucose
correlation with glycemia or HbA1c issue were ‘‘saliva and blood
and glucose’’, ‘‘salivary and glucose and correlation’’, ‘‘salivary
and glucose and glycemia’’, ‘‘glucose and saliva and A1c’’,
‘‘glucose and saliva and correlation’’, ‘‘sugar and saliva and
correlation’’, ‘‘glucose and saliva and association’’ and ‘‘sugar and
saliva and association’’.
Literature screening
Papers were evaluated for their relevance first by assessing the
title and second by abstract evaluation. The selected titles were
then fully assessed for eligibility. Salivary glucose results in both
concentration (e.g. mg/dl) and excretion rate (e.g. mg/dl/min) were
accepted. Importance was given to saliva being collected as a
whole (mixed saliva) after fasting for at least one hour (except for
the salivary glucose/glycemia correlation data) and in an
unstimulated way, since previous saliva experiments performed
in our lab without these constraints had yielded inconsistent
results. Abstracts and papers in languages other than English were
excluded and author(s) were asked for an English copy if possible.
Two studies [11,15] with the same relevant data also present in
posterior published reports [19,22] were excluded in favor of
respective posterior reports. Records were also excluded if the full-
text articles were not available online and the author(s) failed to
send a copy or did not supply required supplementary data. Two
studies [16,18] were rejected because the diabetic group was a
mixture of type 2 and type 1 diabetic patients, potentially creating
biases and heterogeneity in the diabetic sample that could skew the
meta-analysis.
Mean salivary glucose levels. Studies were excluded unless
they consisted strictly of diabetes mellitus type 2 data versus healthy
controls and were about unstimulated whole saliva collected under
fasting conditions, with a fasting period of at least 1 hour.
Correlations with salivary glucose levels. Studies were
excluded unless they contained correlation data between glycemia
or HbA1c and salivary glucose from unstimulated whole saliva
collected from strict diabetic type 2 patients or in a healthy group
of individuals. A fasting period of at least 1 hour was required
prior to blood and saliva collection for studies to be included, if the
correlation involved HbA1c. No fasting period was required for
the inclusion of studies looking at correlations with glycemia.
Critical evaluation of data
Mean salivary glucose levels. Using the approach outlined
in the previous section, nine studies were selected, and combined
with our own unpublished results. Means, standard deviations and
sample sizes were collected from each study for the diabetic and
control groups. In studies in which the diabetic group was split into
two subsets, for instance controlled and uncontrolled diabetes
[14,19], with periodontitis and without it [22], or obese and non-
obese diabetics [10], the two were pooled and combined (or
composite) sample sizes, means and standard deviations were
calculated. Composite standard deviations were obtained as
reported by Headrick [31], through the square root of the
composite variance. Therefore, in studies with subsets some
characteristics of diabetes may be distributed in the diabetic group
in a non-random fashion. Although those studies were not
removed from the review, they were classified as studies with
increased risk of bias and treated as a subgroup in meta-analysis.
Correlations with salivary glucose levels. Six studies were
selected to assess the correlation between salivary glucose levels
and glycemia (totaling seven studies with our unpublished data).
Only two studies were selected from the screening for correlation
with HbA1c, three after including our data. Correlation coeffi-
cients, associated significance and sample sizes were collected from
each study in order to perform the meta-analysis.
Power analysis
Post hoc power analysis for t test and ANOVA were undertaken
using G*Power 3.1.5 software [32].
Meta-analysis
Meta-analysis calculations and graphical plots, except for forest
plots, were performed with R version 3.0.0 [33] specific packages
described below. Forest plots and associated calculations were
made with OpenMeta[Analyst] 6.7.13 program [34] from studies
results after effect sizes and associated 95% confidence intervals
(CI) calculations. Quantity I2 was measured to assess the degree of
dispersion of effect sizes and the overall homogeneity statistical
significance was calculated through the x2 test [35]. All tests were
Effect of Diabetes Mellitus Type 2 on Salivary Glucose
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two-tailed with alpha set at 0.05 except for homogeneity test whose
significance level cutoff was considered to be 0.10 due to the low
power of the x2 test with a limited amount of studies.
Mean salivary glucose levels. Since not all reported means
were using the same units for salivary glucose, a Hedge’s
standardized mean difference g was first calculated as effect size
(ES). Hedge’s g is a group difference ES index used to measure the
magnitude of difference between two groups. It is resilient to
variation in sample sizes, and allows for a standardized compar-
ison across studies using different measures for the same variable.
Calculation of this index is important since large g values indicate a
better clinical applicability of the identified differences. We
followed Cohen’s [36] conservative conventions for Hedge’s g
effects: small $0.20, medium $0.50 and large $0.80. Confidence
Intervals (CI) associated with each g ES index were used to assess
the reliability of the effect, since a wide CI are an important way to
evaluate the precision of a study’s findings by providing a range of
likely values around the obtained g ES. To further evaluate and
discuss g ES results we followed Coe’s interpretation table for ES
[37]. For Hedge’s g calculations and for graphical plot generation,
salivary glucose means, standard deviations and sample sizes were
inserted in R version 3.0.0 as raw data, and fed to the R packages
‘MAd’ for Hedge’s g ES and CI calculation and to ‘Metafor’ to
build the random effects aggregation model (DerSimonian-Laird
method) followed by graphical plotting. Diabetic group allocation
(with subsets, without subsets) was used as grouping factor in the
model, since sample allocation heterogeneity can be an important
source of bias in meta-analysis [38]. The following moderator
candidates were evaluated through a mixed-effects meta-regres-
sion model: mean age difference between the two groups (type 2
DM versus control), mean age of the diabetic group and fasting
hours prior to sample collection, and statistical power of the study.
The possibility of publication bias was evaluated using a Begg’s
contour-enhanced funnel plot corrected with the trimfill function
of R ‘‘Metafor’’ package.
Correlations with salivary glucose levels. To evaluate the
global correlation strength between salivary glucose level and
glycemia or HbA1c, Pearson correlation coefficients (r) and sample
size values were collected from each study and used to calculate ES
estimates as transformed Fisher-z coefficients and associated
standard errors through the respective formulas. This is a
necessary step because although r is the most commonly used
strength of association ES index, calculating standard errors for
such correlation coefficients is difficult. Moreover, the distribution
of r becomes skewed as the population value of r deviates from
zero, and converting r to Fisher’s z corrects for this skew [39].
Finally, we ran our normalized Fisher-z data through the R
package ‘meta’ metagen function to calculate an overall normal-
ized Fisher-z, using a random effects model (DerSimonian-Laird
method), and through the ‘metafor’ R package for graphical plot
generation. The data from diabetic and non-diabetic studies were
aggregated both as a whole and as subgroups in the analysis.
Finally, in order to place the overall ES back in a correlation
framework, we converted the aggregated Fisher-z data back to
Pearson’s r correlation coefficients running the R package ‘psych’
fisherz2r transformation function, and applied Cohen’s conven-
tions [36] for r effect evaluation: small $0.10, medium $0.30 and
large $0.50. High r values indicate a stronger correlation.
To evaluate if the strength of the association between salivary
glucose and glycemia/HbA1c increased with the higher values of
glycemia/HbA1c typically associated with type 2 DM we applied
again an r to z Fisher transformation to the correlation data and
calculated respective standard errors from each study containing
estimates for both diabetic and control groups. Afterwards we
estimated Cohen’s q ES statistic [36], a measure of the difference
between Fisher-z results across the diabetic and control groups.
Cohen’s q ES standard errors were calculated using standard error
propagation estimations from Fisher-z data standard errors.
Aggregated Cohen’s q ES were calculated as previously reported
for overall Fisher-z values. To evaluate these overall ES we
followed Cohen’s conventions for q effects [36]: small $0.10,
medium $0.30, large $0.50. If the associated CI did not overlap
with zero, the effect was considered significant, as this suggests that
Cohen’s q scores are likely to represent a true difference. High q
values indicate a meaningful difference between two correlations.
Results
Flow of study selection
Mean salivary glucose levels. The flow of study selection
for the mean salivary levels is displayed in Figure 1. Our database
search initially retrieved 4040 records. After screening for relevant
titles, we excluded 3982 records that were either not relevant or
duplicated, and identified 63 potentially relevant studies that were
assigned for abstract level evaluation. Four additional non-
duplicated relevant records were identified through references
found in the selected articles, and pooled with the other 63
potentially relevant studies. Among these, 9 records were selected
Figure 1. Flow of study selection for mean salivary glucose
levels. *Studies were excluded unless contained salivary glucose data
(means, standard deviations and sample size) obtained from strictly
diabetes mellitus type 2 patients and non-diabetic controls unstimu-
lated whole saliva collected after a minimum fast period of 2 hours.
Were also excluded if the full-text article were not available and the
author(s) failed in sending a copy after contact request or failed in
giving back supplementary required data inexistent in the original
article. Records containing data already published in other article were
also excluded.
doi:10.1371/journal.pone.0101706.g001
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after full-text article assessment and combined with our unpub-
lished data, adding up to a final cluster of 10 studies.
Correlations with salivary glucose levels. A new elec-
tronic search was made following a similar procedure as the
previous one, producing 3286 references. The examination of the
titles allowed us to reject 3270 records that were not relevant, and
retrieve a preliminary list of 16 potentially relevant studies. Of
these, 4 were selected after abstract and full-text assessment, to
which we added one non-duplicated eligible article identified in
our previous search for ‘‘salivary glucose means’’, and our
unpublished data, resulting in a final cluster of 7 studies.
Studies characteristics
Table 2 lists the main characteristics of the 14 studies, including
our own. Ten of these were included in the meta-analysis of
salivary glucose means (Fig. 2), adding up to a total sample of 580
type 2 DM patients and 297 non-diabetic controls. From these
studies, only 7 were included in the meta-analysis of salivary
glucose and glycemia/HbA1c correlation (Figs. 3 and 4). These
studies included articles published between 1998 and 2012 and
our own unpublished report. Four studies were based in India, two
in Brazil and two in Iran. The remaining studies all took place in
different countries: Turkey, Iraq, Nigeria, Japan, Pakistan and
Portugal. The majority of the studies were conducted on patients
of clinics or hospital centers, which allocated them into different
diabetic groups. All the studies except one adopted exclusion
criteria regarding the population sampling for type 2 DM and/or
control groups, although the adopted criteria were not the same
for all the studies. The majority of the studies complied with an
overnight fasting period prior to sampling, two studies guaranteed
only 2 hours of fasting before sampling, and another two studies
reported a minimum of 90 minutes of fasting; in one study that
information was not reported. Type 2 DM participant’s informa-
tion about diabetes duration, concomitant medications or addi-
tional disorders was missing in all studies. In two studies salivary
glucose was measured through the glucose oxidase/phenol and
aminophenazone method (GOD-PAP), while in the remaining
studies the glucose oxidase-peroxidase method (GOD-POD) was
used. Significant differences in salivary glucose between type 2
DM and healthy controls were reported in 7 studies. Among the 7
studies that examined the correlation between salivary glucose and
glycemia, 5 reported results on type 2 diabetics while 6 reported
results on healthy individuals. Only 3 studies reported glucose/
HbA1c correlation data in type 2 diabetics, of which only 2 also
examined healthy individuals.
Data analysis
Mean salivary glucose levels. Initially we established which
salivary glucose sampling conditions (e.g. minimum fasting period)
were needed to obtain consistent salivary glucose measurements in
our experiment, an essential step for the detection of differences in
salivary glucose levels between type 2 DM and non-diabetics.
Table 3 shows the salivary glucose measurements taken from 45
diabetics and 16 controls, all of them fasting individuals. These
results were included in the standardized mean difference meta-
analysis and show a very significant difference (p,0.01) between
the salivary glucose values obtained from diabetic and control
groups.
We evaluated test significance, power, Hedge’s g and ES
interpretation according to Cohen’s conventions for each of the
studies included in the meta-analysis (including our own, Table 4).
Three studies failed to detect significant differences between the
type 2 DM and control groups (p.0.1) [23–25], probably because
they used samples of small or medium sizes, and were likely to be
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underpowered (i.e. power ,0.80), which may account for the lack
of statistically significant effects identified in ANOVA and t tests.
The other seven studies, where significant differences were found
(p,0.05), were all well-powered studies (power .0.80), with the
exception of Vasconcelos study [12] with 75% of power. All
studies except one [25] found an increase in salivary glucose
concentration/secretion in type 2 diabetics, yielding an estimated
medium to large positive effect. Furthermore, the overall positive
large Hedge’s g ES (1.37), obtained by applying a random effects
model to the combined results of the studies of mean salivary
glucose, also suggests a meaningful difference between the DM
results and those from non-diabetic controls.
To have an historical perspective of this effect we plotted a
cumulative forest plot. In Fig. 5 we can observe that earlier studies
suggested a larger positive effect than the one obtained from
analyzing the whole available dataset but also had lesser precision
(represented by an increased CI) than the actual overall
aggregated studies.
To acknowledge for the possible contribution of a selection bias
to heterogeneity in the overall model regarding DM sample
allocation type (with and without subsets), we performed a
subgroup meta-analysis (Fig. 2) using the Hedge’s g data from all
selected studies (including our own) grouped in two clusters: one
containing studies with subsets in the DM group (mixture of DM
patients previously allocated to two groups) and the other one
without subsets in the DM group. We verified that there was
significant heterogeneity among all studies (I2 = 94%, p,0.10) but
also within subgroups (p,0.10). The subgroup analysis (Fig. 2)
showed that a substantial fraction of the heterogeneity came from
studies with DM group subsets. If we look at the other subgroup of
studies (without subsets), the heterogeneity value decreases to 50%.
Furthermore, the latter shows an overall effect value of 0.52
(medium effect), with a [0.21,0.84] CI, which is smaller than the
aggregated ES value for the combined dataset (1.37[0.67,2.07];
large effect), and also smaller than the value obtained for the
subgroup with subsets of type 2 DM, which presents the largest ES
(2.74[0.95,4.53]). The precision of the estimates of ES, all non-
overlapping with zero CI, also differed between the subgroups,
with the subgroup containing subsets of type 2 DM patients
showing the widest CI. Therefore, results show that randomization
in type 2 DM sampling is an important factor that affects the
reliability of salivary glucose levels.
Since significant heterogeneity was detected even in the
subgroup without subsets of DM patients, we further investigated
the potential contribution of some candidate moderators: mean
age difference between the two groups, mean age of the diabetic
group, fasting hours prior to sample collection and study statistical
power. To do so, we included them in a mixed-effects meta-
regression model, which failed to detect a significant effect for any
Figure 2. Subgroup forest plot of type 2 DMmean salivary glucose levels studies. Studies have been grouped according to the type 2 DM
group allocation: with or without subsets. Hedge’s g (standardized mean difference) effect size estimates have been calculated with 95% confidence
intervals and are shown in the figure. Area of squares represents sample size, continuous horizontal lines and diamonds width represents 95%
confidence interval. Yellow diamonds center indicates the subgroup pooled estimates while the blue diamond center and the vertical red dotted line
both point to the overall pooled estimate. For more detailed results see Table 2 and 4.
doi:10.1371/journal.pone.0101706.g002
Figure 3. Contour-enhanced funnel plot with publication bias
correction for the studies without type 2 DM subsets. Under the
sensitivity analysis of the results to publication bias a trim and fill white
dot was added and the plot was horizontally adjusted to maximize the
dots distribution symmetry. The white region in the middle corresponds
to p-values greater than 0.1, the gray-shaded region corresponds to p-
values between 0.1 and 0.05, the dark gray-shaded region corresponds
to p-values between 0.05 and 0.01, and the region outside of the funnel
corresponds to p-values below 0.01.
doi:10.1371/journal.pone.0101706.g003
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of them. Finally, we tested for an eventual publication bias among
the subgroup of studies with no subsets of type 2 DM (Fig. 3) by
applying the trim and fill correction [39]. This adjustment, with
the addition of one virtual ‘‘no effect’’ study, decreased the overall
ES in this subgroup from 0.52 (medium effect) to 0.44 (small-
medium effect) and increased I2 from 50% to 58%.
Correlations with Salivary glucose levels. The results
from our meta-analysis of mean glucose levels prompted us to
further analyze the correlation between salivary glucose and
glycemia (Table 5) or HbA1c (Table 6). Our own unpublished
results, posted in Table 3, yield significant correlations (p,0.05)
between salivary glucose and glycemia/HbA1c only in the type 2
DM group, and even then only a low strength correlation was
found.
Glycemia. Table 5 summarizes the correlations reported
between salivary glucose levels and glycemia for the type 2 DM
group: three studies found a high correlation [9,13,21], one study
reported no correlation [25] and our own study detected a
medium-strength one. In the control group, the values were on
average lower, with half of the studies (including our own)
reporting no correlation, while the other half found medium to
weak correlations.
To assess the general ES of the correlation between glycemia
and salivary glucose, we performed a subgroup meta-analysis
(Fig 4) using the correlation coefficients data from all the selected
studies (including our own), transformed into Fisher-z ES estimates
(see Methods for more details), and grouped into two clusters: one
containing studies of type 2 DM patients and the other one
containing studies that included non-diabetic subjects. The overall
Fisher-z results were again converted to the more intuitive
Pearson’s r correlation coefficients.
There was significantly high heterogeneity amount among all
studies (I2 = 89%, p,0.10) and within the DM subgroup
(I2 = 89%, p,0.10), while in the control subgroup heterogeneity,
while still significant, was lower (I2 = 59%, p,0.10). The diabetic
subgroup included four published reports and our own results and
showed a large overall correlation (r = 0.67/z= 0.77[0.43,1.10])
between salivary glucose and blood glucose, while for the control
group the combined correlation was smaller (r = 0.30/
z= 0.31[0.02,0.59], medium effect). The overall correlation
coefficient when both subgroups were included, was 0.49
(z = 0.54[0.25,0.82]) (medium-large effect). All these three corre-
lation coefficients came from Fisher-z values, and had CI similar in
precision and non-overlapping with zero. The larger correlation
observed for the DM subgroup suggests that, in type 2 diabetic
Figure 4. Subgroup forest plot of salivary glucose levels correlations with glycemia. Studies have been grouped according to the sample
group type: type 2 diabetics or non-diabetics (control). Standardized Fisher-z effect size estimates have been calculated with 95% confidence intervals
and have been aggregated (random effects model). Area of squares represents sample size, continuous horizontal lines and diamonds width
represents 95% confidence interval. Yellow diamonds center indicates the subgroup pooled estimates while the blue diamond center and the vertical
red dotted line both point to the overall pooled estimate. For more detailed results see Table 2 and 5.
doi:10.1371/journal.pone.0101706.g004
Table 3. Salivary glucose correlations, means and standard deviation (sd) results in type 2 DM group versus control.
Type 2 DM (mean±sd) N=45 Control (mean±sd) N=16
Salivary glucose mg/ml 0.8860.24* 0.5660.47
Salivary glucose/glycemia correlation 0.40** 0.17
Salivary glucose/HbA1c correlation 0.34** 0.08
N- sample size. *significantly different from control group (p,0.01); **medium strength significant correlations (p,0.05). according to Cohen’s convention [36] for r
effects.
doi:10.1371/journal.pone.0101706.t003
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patients, increases in glycemia are paired with a stronger positive
effect on the level of salivary glucose compared with non-diabetic
individuals. The correlation appears to be stronger for higher
values of glycemia. To further support this possibility we tested the
effect of type 2 DM (i.e. glycemia increase) on r strength applying
the Cohen’s q statistic.
In four studies, it was possible to calculate Cohen’s q statistic.
Cohen’s q results were not consistent, and varied from a large ES
to an absence of meaningful effect. These q values were used as ES
estimates to build a random effects model, as shown in Fig. 6.
Overall, the Cohen’s q results estimated a significant medium
strength 0.35[0.09,0.62] ES, with a non-overlapping zero CI,
confirming a stronger correlation between salivary glucose and
glycemia in type 2 DM relative to the non-diabetic control.
HbA1c. A summary of the meta-analysis of the correlation
between salivary glucose and HbA1c is presented in Fig. 4. It
included two published reports, in addition to our own results, for
the diabetic subgroup, and only one published report, as well as
our own data, for the non-diabetic control subgroup. All studies
reported a medium correlation in the diabetic subgroup, while for
the non-diabetic subgroup both studies failed to detect a significant
correlation (Table 6).
It should be noted that, given their more straightforward
physiological link, the correlation between salivary glucose and
glycemia is expected to be stronger than between salivary glucose
and HbA1c, and so it is unsurprising that the correlation values
present in Table 5 are in average higher than the one’s present in
Table 6.
Table 4. Total sample size (N), significance (Sig.), power, Hedge’s g and effect size evaluation of 10 salivary glucose observational
studies in type 2 DM subjects and controls.
Study N DM/control Sig. Power Hedge’s g Effect size evaluation
Aydin 2007 * 40/22 ,0.0001 £,D 99.99% 4.256 large
Vaziri 2010 40/20 0.1900 £ 11.77% 0.208 small
Hegde 2010 26/21 0.28301 47.54% 0.559 medium
Vasconcelos 2010 40/40 0.0360 £,D 74.88% 0.604 medium
Panchbhai 2012 * 180/90 ,0.0001 £,D 99.99% 1.041 large
Abikshyeet 2012 106/15 0.0017 £,D 88.54% 0.880 large
Al-Zahawi 2012 * 60/30 ,0.0001 £,D 99.99% 4.579 large
Manjrekar 2012 23/23 0.7241£ 6.39% 20.103 no effect
Lasisi 2012 * 20/20 0.0004£,D 96.44% 1.198 large
Own unpublished data 2013 45/16 0.0009£,D 96.10% 1.003 large
Aggregated data (random effects model) 580/297 ,0.0001** 99.99% 1,372 large
Power values are relative to Hedge’s g effect sizes for each study and aggregated data. Effect size evaluation was made following Cohen’s conventions [36] for Hedge’s
g effects: small $0.20, medium $0.50, large $0.80.
£ t test significance, 1ANOVA significance, * combined data from type 2 DM subsets, ** omnibus random effects model significance, D zsignificant (p,0.05).
doi:10.1371/journal.pone.0101706.t004
Figure 5. Cumulative forest plot of type 2 DM mean salivary glucose levels studies. Ten studies have been added and aggregated
(random effects model). Hedge’s g (standardized mean difference) effect size estimates have been calculated with 95% confidence intervals in a
cumulative and chronological way. Area of squares represents sample size, continuous horizontal lines represents 95% confidence interval and the
vertical red dotted line indicates the pooled random effect weighted estimate.
doi:10.1371/journal.pone.0101706.g005
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Once again, to estimate the overall correlation between HbA1c
and salivary glucose, a subgroup meta-analysis was performed
(Fig. 7) using Fisher-z transformed data from all selected studies
(including our own) grouped into two clusters: one containing
studies in type 2 DM patients and the other one containing studies
that included non-diabetic control subjects. The meta-analysis
yielded an overall medium correlation (r = 0.37/
z= 0.39[0.17,0.62]) between salivary glucose and HbA1c with
Fisher-z CI non-overlapping with zero. In the diabetic studies
subgroup the correlation was stronger (r = 0.50/
z= 0.55[0.39,0.71]) with Fisher’s z CI non-overlapping with zero
while a non-significant correlation (r = 0.11/z= 0.11[20.15,0.36])
was found in the non-diabetic subgroup. Similar to what we
observed for the glycemia/salivary glucose correlation, our
estimates of the correlation between HbA1c and salivary glucose
for type 2 DM and control subgroups (Figs. 7) suggest that, in type
2 diabetic patients, increases in HbA1c values are more strongly
correlated with increases in salivary glucose than in non-diabetic
control groups, where HbA1c values are on average smaller.
There was overall high heterogeneity among all the studies
(I2<65%, p,0.10). A subgroup analysis showed that a significant
fraction of the heterogeneity originated from the diabetic studies,
while in the other subgroup of studies (without diabetics), the level
of heterogeneity is low.
The correlations between HbA1c and salivary glucose for type 2
DM and control subgroups were compared using Cohen’s q
statistic in two studies, in the one from Mahdavi [21] and in our
own, showed a medium and a small ES, respectively. These results
were used as ES estimates to build a random effects model, which
yielded an overall medium strength q ES of 0.40[0.06,0.74] (CI
non-overlapping with zero but with low precision, Fig. 8). Cohen’s
q ES meta-analysis result shows that the correlation between
salivary glucose and HbA1c mirrors the previous correlation
behavior between salivary glucose and glycemia, in that correla-
tions are stronger within type 2 DM groups (or for increased
glycemia) then in the non-diabetic control groups.
Discussion
We have performed the first systematic review of the effect of
type 2 DM on salivary glucose levels, to evaluate if the increase in
salivary glucose levels associated with type 2 DM is both strong
and consistent enough to substantiate salivary glucose as a
potential type 2 DM biomarker. This evaluation was motivated
by the historical controversy surrounding this issue, with some
Figure 6. Forest plot from DM condition effect on salivary glucose levels correlations with glycemia. Cohen’s q (standardized Fisher-z
difference between diabetic and control groups) effect size estimates have been calculated with 95% confidence intervals and have been aggregated
(random effects model). Area of squares represents sample size, continuous horizontal lines and diamonds width represents 95% confidence interval
and the diamonds centre and vertical red dotted line indicates the pooled random effect weighted estimate. For more detailed results see Table 5.
doi:10.1371/journal.pone.0101706.g006
Figure 7. Subgroup forest plot of salivary glucose levels correlations with HbA1c. Studies have been grouped according to the sample
group type: type 2 diabetics or non-diabetics (control). Standardized Fisher-z effect size estimates have been calculated with 95% confidence intervals
and have been aggregated (random effects model). Area of squares represents sample size, continuous horizontal lines and diamonds width
represents 95% confidence interval. Yellow diamonds center indicates the subgroup pooled estimates while the blue diamond center and the vertical
red dotted line both point to the overall pooled estimate. For more detailed results see Table 2 and 6.
doi:10.1371/journal.pone.0101706.g007
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authors defending the idea that salivary glucose based tests have
the potential to become an effective and non-invasive method for
diagnosing or monitoring DM, and others vividly dismissing it.
A few previous reports of salivary glucose measurements in
diabetic patients included reviews of this subject, but mainly from
a qualitative point of view. Furthermore, strict criteria for study
inclusion were not always adopted or explicit, and differences
regarding sample allocation and experimental design were
generally not taken into account, potentially leading to increased
selection bias. These earlier reviews (see Introduction) often
disagree on the size of the difference between salivary glucose
levels in type 2 DM and non-diabetics based on null-hypothesis
significance testing data, and on the strength of the correlation
between glycemia/HbA1c and salivary glucose, all of which are
essential to assess the potential of salivary glucose for screening
potential diabetic patients.
We also found that, over the years, the global Hedge’s g ES of
type 2 DM on salivary glucose changed from an initial imprecise
but very high value to the current more precise and significant
large value of 1.37. This progression may be a consequence of the
legacy of a publication bias, or of non-random allocation of type 2
DM patients, with a recent adoption of a stricter glycemic control
by type 2 DM patients, in combination with the increased
precision in overall estimates achieved by increasing the number of
studies included in meta-analysis. In this review, we tried to
minimize study selection bias by including only published reports
where saliva was being collected under similar conditions as the
ones we used in our experiments.
The large overall ES value obtained from the standardized
mean difference meta-analysis (1.37), according to Coe’s interpre-
tation table for standardized mean difference ES [37], means that
the probability that the salivary glucose level of a type 2 DM
patient exceeds the salivary glucose level of a non-diabetic is 83%,
if both are chosen at random. Accordingly, the average salivary
glucose score of a type 2 DM patient exceeds 91% of control
salivary glucose levels values. Global ES estimates obtained from
aggregated type 2 DM and non-diabetic controls studies of the
correlation between salivary glucose and glycemia/HbA1c yielded
consistent medium to large effects (0.49/0.37), which increased
further in strength when the correlation synthesis was limited to
data from type 2 DM patients (0.67/0.50), which had, on average,
higher glycemia/HbA1c values. This stronger correlation within
the type 2 DM subgroup suggests that the salivary glucose
secretion rate increase is somehow more strongly paired with
blood glucose/HbA1c on a chronic hyperglycemia background, as
previously reported by Abikshyeet [13]. It is known that DM
chronic hyperglycemia leads to microvasculature structural
changes, as well as basement membrane alterations in salivary
glands and soft oral tissues [40–42]. These changes result in leaky
salivary glands and soft oral tissues, leading to an increase on the
glucose diffusion rate from the blood to the oral cavity [13,43].
These oral physiological changes associated with DM could
therefore explain the increase in the strength of the correlation
between the salivary glucose and glycemia/HbA1c in the type 2
DM subgroup.
In the non-diabetic control groups, the results of our meta-
analysis of the correlation of salivary glucose levels showed a
medium effect with glycemia and a non-significant effect with
HbA1c. This lower effect may be related with a less permeable
salivary glands/oral mucosa present in healthy individuals and/or
with a possible detection limit of the employed glucose measure-
ment technique (GOD-POD/GOD-PAP) for very low concentra-
tions of salivary glucose. If the latter is true, saliva-based tests may
be of limited use to monitor blood glucose levels in non-diabetics
or diabetics with very good metabolic control of the disease.
There are other potential limitations to this systematic review.
One potential source of bias includes the possible misclassification
of subjects into the control or DM groups. Another issue is that our
findings are based on the results of observational studies and that
we can therefore not exclude the presence of confounding factors,
especially relevant when ES are not very high. Studies included in
our systematic review did not consistently report some important
sample-related potential moderators, such as mean duration of
DM, and status of glycemic control and treatment, preventing
these variables from being tested as sources of heterogeneity.
These factors, combined with differences in the procedures used in
each study, may confound the outcome and partly explain the
significant amount of heterogeneity detected in the meta-analyses
of salivary glucose means and correlations. Heterogeneity may also
be due to the presence of subsets (obesity, bad metabolic control or
periodontitis) in type 2 DM groups that may change the proportion
of patients with poor metabolic control. Furthermore, the lack of
statistical significance found for the effect of tested moderators on
the heterogeneity should be seen with caution, because of the
limited statistical power provided by the small number of studies
included in the meta-regression model. Up to now, no studies have
examined the sensitivity/specificity of salivary glucose testing for
evaluating blood glucose or even screening or monitoring type 2
DM. In the future, it will be important to define the predictive
power of salivary glucose to estimate glycemia/HbA1c levels as
well as its sensitivity and specificity. Despite these limitations and
the reduced number of observational studies reviewed, some of
them with small sample sizes, the consistency of the overall ES of
salivary glucose mean and correlation with glycemia and HbA1c
Figure 8. Forest plot from DM condition effect on salivary glucose levels correlations with HbA1c. Cohen’s q (standardized Fisher-z
difference between diabetic and control groups) effect size estimates have been calculated with 95% confidence intervals and have been aggregated
(random effects model). Area of squares represents sample size, continuous horizontal lines and diamonds width represents 95% confidence interval
and the diamonds centre and vertical red dotted line indicates the pooled random effect weighted estimate. For more detailed results see Table 6.
doi:10.1371/journal.pone.0101706.g008
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support the claim that type 2 DM have a positive medium to large
overall effect on salivary glucose levels. This substantiates the use
of this variable for type 2 DM screening, especially in large-scale
studies, which could be greatly facilitated by the ease of the
methodology. Furthermore, this correlation between blood and
salivary glucose levels grows with increased glycemia or HbA1c,
which may, in itself, be a sign of diabetes with bad metabolic
control. Salivary glucose evaluation may therefore also facilitate
the monitoring of metabolic status in DM patients through daily
glucose self-measurements.
In conclusion, our results show that type 2 DM leads to a
consistent increase in salivary glucose that remains detectable in
spite of food contamination, variations in salivary flow rate or
presence of local autonomic neuropathy. Our review also reports a
significant overall relationship between salivary glucose concen-
tration and associated glycemia/HbA1c values, with the correla-
tion strength increasing as we move to higher glycemia/HbA1c
values. These results, in combination with recent and old reports
[13,30], support the possible use of salivary glucose as type 2 DM
biomarker. If associated with the development of sensitive portable
technology to measure salivary glucose [30,44,45] this will allow a
less painful and invasive method for type 2 DM screening or
diabetic glucose monitoring, especially for studies of large cohorts.
Even if at present, due to several limitations, salivary glucose per se
may not show enough consistency to be used as an independent
and autonomous DM type 2 biomarker, our results suggest that it
provides valuable information, and may in the future be combined
with other salivary biomarkers to create an effective high
sensitivity/specificity DM type 2 large-scale screening system.
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